METABOLIČKI SINDROM U HOSPITALIZIRANIH BOLESNIKA S PSORIJAZOM

Backround: Recent studies suggest a link between psoriasis and metabolic syndrome. The aim of our study was to demonstrate the prevalence of metabolic syndrome in our hospitalized psoriatic patients. Methods: A hospital-based, cross - sectional study with 49 psoriatic patients was conducted from January 1th 2015 to December 31th 2015 in the Dermatology and Venerology department, University Hospital of Split. Metabolic syndrome was defined by the International Diabetes Federation (IDF) guidelines. Results: In this investigation 47% of the hospitalized psoriatic patients had the metabolic syndrome, whereas 53% had not. Gender (p=0.281), disease duration (p=0.936) and disease onset (p=0.237) did not play a statistical significant role in relation to the metabolic syndrome. Similarly, we could not find a higher prevalence of metabolic syndrome in regard to age (p=0.146). Our psoriatic patients had joint involvement in 57% of cases, however we did not show a correlation between joint involvement and the metabolic (p=0.836). Psoriatic patients had a high prevalence of co-morbidities (75%), and it was significantly high (91%) in those psoriatic patients who had the metabolic syndrome (p= 0.037). Systolic blood pressure was increased in 56 % of patients with the metabolic syndrome, 39% had increased diastolic blood pressure and of those had 28% already diagnosed hypertension. In this study 70 % of patients with metabolic syndrome had increased fasting glucose and of those patients 16% had already diagnosed diabetes mellitus. Our study showed a significant correlation between psoriasis and co-morbidities, which are associated with the metabolic syndrome. Conclusion: Metabolic syndrome is prevalent in psoriatic patients. As a general consideration all psoriatic patients should be advised to change their life style, if necessary early treatment should be advised and regularly follow up of patients with increased risk to develop metabolic syndrome. Management of psoriasis should be an integrated approach due to its increased correlation with other co-morbidities.Cilj: Nedavne studije upućuju na povezanost vulgarne psorijaze i metaboličkog sindroma. Cilj našeg istraživanja bio je istražiti prevalenciju metaboličkog sindroma u hospitaliziranih bolesnika s psorijazom. Metode: Od 1. siječnja 2015. do 31. prosinca 2015. provedena je presječena studija sa 49 hospitaliziranih bolesnika sa psorijazom, u Klinici za dermatologiju i venerologiju, Kliničkog bolničkog centra Split. Metabolički sindrom je definiran smjernicama International Diabetes Federation (IDF). Rezultati: U ovom istraživanju 47% hospitaliziranih bolesnika imalo je metabolički sindrom, dok 53% nije. Spol (p=0,281), trajanje bolesti (p=0,936), niti početak bolesti (p=0,237) nisu imali statistički značajnu ulogu u odnosu na metabolički sindrom. U ovoj studiji dob nije imala statističku značajnost (p=0,146) u odnosu na metabolički sindrom. Ispitivani bolesnici imali su zahvaćene zglobove u 57% slučajeva, što se nije pokazalo značajnim u odnosu na metabolički sindrom (p=0,836). Bolesnici sa psorijazom su imali veliku prevalenciju komorbiditeta (75%), a značajno su bili visoki (91%) kod pacijenata koji su imali metabolički sindrom (p = 0,037). U 56% bolesnika sa metaboličkim sindromom uočeno je povišenje sistoličkog krvnog tlaka, a 39% je imalo porast dijastoličkog krvnog tlaka dok je u 28% već prethodno dijagnosticirana hipertenzija. U ovom istraživanju 70% bolesnika sa metaboličkim sindromom imalo je povišene vrijednosti glukoze u krvi natašte, a među njima 16% je već imao dijagnosticiran dijabetes. Pokazano je da postoji značajna korelacija između vulgarne psorijaze i komorbiditeta, posebno onih čimbenika koji su povezani sa metaboličkim sindromom. Zaključak: Metabolički sindrom je prisutan kod bolesnika s psorijazom. Kao opći zaključak, svim bolesnicima sa psorijazom bi trebalo savjetovati promijenu načina života. Preporučuje se rano liječenje i redovno praćenje bolesnika s povećanim rizikom za razvoj metaboličkog sindroma. Liječenje vulgarne psorijaze bi trebalo imati integrirani pristup zbog povećane povezanosti upalnih promjena sa drugim organskim sustavima i posljedične pojave komorbiditeta